Literature DB >> 19218083

Aligning antimicrobial drug discovery with complex and redundant host-pathogen interactions.

Sarah L Lebeis1, Daniel Kalman.   

Abstract

Drug-resistant microorganisms pose an enormous threat to public health. Here we provide examples of experimental approaches that offer novel ways to think about drug development considering the complexity inherent to host-pathogen interactions. Emergent themes include (1) targeting pathogenicity rather than microbial growth, (2) targeting the host or host-pathogen interface rather than the pathogen, (3) facilitating pathogen-specific immune responses, and (4) utilizing systems-based approaches to identify new drug targets and validate drug efficacy. We posit that together these approaches may allow identification of drugs that disrupt pathogenesis and allow the immune system time to protect, but do not easily engender resistance.

Mesh:

Substances:

Year:  2009        PMID: 19218083     DOI: 10.1016/j.chom.2009.01.008

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  16 in total

1.  Dissecting novel virulent determinants in the Burkholderia cepacia complex.

Authors:  George P Tegos; Mark K Haynes; Herbert P Schweizer
Journal:  Virulence       Date:  2012-05-01       Impact factor: 5.882

Review 2.  ESKAPEing the labyrinth of antibacterial discovery.

Authors:  Ruben Tommasi; Dean G Brown; Grant K Walkup; John I Manchester; Alita A Miller
Journal:  Nat Rev Drug Discov       Date:  2015-07-03       Impact factor: 84.694

3.  Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis.

Authors:  Ruth J Napier; Wasiulla Rafi; Mani Cheruvu; Kimberly R Powell; M Analise Zaunbrecher; William Bornmann; Padmini Salgame; Thomas M Shinnick; Daniel Kalman
Journal:  Cell Host Microbe       Date:  2011-11-17       Impact factor: 21.023

4.  The overlap of small molecule and protein binding sites within families of protein structures.

Authors:  Fred P Davis; Andrej Sali
Journal:  PLoS Comput Biol       Date:  2010-02-05       Impact factor: 4.475

5.  The Mycobacterium tuberculosis drugome and its polypharmacological implications.

Authors:  Sarah L Kinnings; Li Xie; Kingston H Fung; Richard M Jackson; Lei Xie; Philip E Bourne
Journal:  PLoS Comput Biol       Date:  2010-11-04       Impact factor: 4.475

6.  Activator of G-Protein Signaling 3-Induced Lysosomal Biogenesis Limits Macrophage Intracellular Bacterial Infection.

Authors:  Ali Vural; Souhaila Al-Khodor; Gordon Y C Cheung; Chong-Shan Shi; Lalitha Srinivasan; Travis J McQuiston; Il-Young Hwang; Anthony J Yeh; Joe B Blumer; Volker Briken; Peter R Williamson; Michael Otto; Iain D C Fraser; John H Kehrl
Journal:  J Immunol       Date:  2015-12-14       Impact factor: 5.422

Review 7.  Drug repurposing for the treatment of staphylococcal infections.

Authors:  Shankar Thangamani; Haroon Mohammad; Waleed Younis; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

8.  Agent-based dynamic knowledge representation of Pseudomonas aeruginosa virulence activation in the stressed gut: Towards characterizing host-pathogen interactions in gut-derived sepsis.

Authors:  John B Seal; John C Alverdy; Olga Zaborina; Gary An
Journal:  Theor Biol Med Model       Date:  2011-09-19       Impact factor: 2.432

Review 9.  Tuberculosis drug discovery in the post-post-genomic era.

Authors:  Benoit Lechartier; Jan Rybniker; Alimuddin Zumla; Stewart T Cole
Journal:  EMBO Mol Med       Date:  2014-01-08       Impact factor: 12.137

Review 10.  Basic and applied uses of genome-scale metabolic network reconstructions of Escherichia coli.

Authors:  Douglas McCloskey; Bernhard Ø Palsson; Adam M Feist
Journal:  Mol Syst Biol       Date:  2013       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.